Schedule 13D ownership disclosure
Bambusa Therapeutics, Inc.
Common Stock, par value $0.001 per share · CUSIP: 058937103
Event date: 2026-10-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 7,429,758.00 · Class: 14.6%
- Peter KolchinskyReported CIK 0001384859
Shares: 7,429,758.00 · Class: 14.6%
- Rajeev ShahReported CIK 0001619841
Shares: 7,429,758.00 · Class: 14.6%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 5,933,787.00 · Class: 11.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001346824-26-000253
- Form type
- SCHEDULE 13D
- Filer
- Bambusa Therapeutics, Inc.
- CIK
- CIK 2044950
- Filed
- Nov 06, 2026
- Reporting period
- Oct 30, 2026
- Description
- Schedule 13D beneficial ownership